News Formycon AG

Equities

FYB

DE000A1EWVY8

Market Closed - Xetra Other stock markets 11:36:15 2024-04-26 am EDT			After market 03:48:48 pm
39.95 ^EUR	+0.63%		39.72	-0.56%

Apr. 25	Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 18	Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance	Apr. 25	EQ
DD: Formycon AG: Dr. Stefan Glombitza, buy	Apr. 24	EQ
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	Apr. 22	AQ
Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024	Apr. 22	EQ
Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast	Apr. 12	EQ
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year	Apr. 12	EQ
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)	Apr. 11	EQ
Fresenius Kabi And Formycon Reach Settlement Agreement For Ustekinumab Biosimilar Candidate In Europe And Canada	Apr. 03	AQ
Updates On Aflibercept BPCIA Litigation	Mar. 26	AQ
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	Mar. 18	MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	Mar. 18	DJ
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada	Mar. 18	EQ
Formycon Wins Regulatory Nod for Lucentis Biosimilar in Saudi Arabia	Mar. 11	MT
FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region	Mar. 11	EQ
Updates On Aflibercept BPCIA Litigation	Feb. 19	AQ
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million	Jan. 30	MT
Gedeon Richter becomes strategic investor of Formycon via equity investment	Jan. 29	EQ
Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor	Jan. 29	EQ
Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023	Jan. 18	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Formycon AG

Equities

FYB

DE000A1EWVY8

Summary

Filters